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Acute neuroprotection in numerous human clinical trials has been an abject failure. Major 
systemic- and procedural-based issues have subsequently been identified in both clinical trials 
and preclinical animal model experimentation. As well, issues related to the neuroprotective 
moiety itself have contributed to clinical trial failures, including late delivery, mono-targeting, low 
potency and poor tolerability. Conditioning (pre- or post-) strategies can potentially address these 
issues and are therefore gaining increasing attention as approaches to protect the brain from 
cerebral ischemia. In principle, conditioning can address concerns of timing (preconditioning could 
be pre-emptively applied in high-risk patients, and post-conditioning after patients experience 
an unannounced brain infarction) and signaling (multi-modal). However, acute neuroprotection 
and conditioning strategies face a common translational issue: a myriad of possibilities exist, 
but with no strategy to select optimal candidates. In this review, we argue that what is required 
is a neuroprotective framework to identify the “best” agent(s), at the earliest investigational 
stage possible. This may require switching mindsets from identifying how neuroprotection can 
be achieved to determining how neuroprotection can fail, for the vast majority of candidates. 
Understanding the basis for failure can in turn guide supplementary treatment, thereby forming 
an evidence-based rationale for selecting combinations of therapies. An appropriately designed in 
vitro (neuron culture, brain slices) approach, based on increasing the harshness of the ischemic-
like insult, can be useful in identifying the “best” conditioner or acute neuroprotective therapy, as 
well as how the two modalities can be combined to overcome individual limitations. This would 
serve as a base from which to launch further investigation into therapies required to protect 
the neurovascular unit in in vivo animal models of cerebral ischemia. Based on these respective 
approaches, our laboratories suggest that there is merit in examining synaptic activity- and 
nutraceutical-based preconditioning / acute neuroprotection.
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1. Introduction 
Human clinical trials examining acute administration of a 
neuroprotective therapeutic after onset of stroke in humans have 
failed (Labiche and Grotta, 2004). This legacy of failure (>100 
trials) has cast a pall on the entire field of neuroprotection 
in stroke. Business decisions to abandon clinical trials of 
neuroprotection in stroke (Choi et al., 2014; Wegener and 
Rujescu, 2013; Howells and Macleod, 2013) have led to a 
trickle-down effect resulting in diminished commitments in 
preclinical cerebral ischemia research. With each clinical 
trial failure, neuroprotection in human stroke is a concept 
increasingly at risk (Savitz and Fisher, 2007). This is despite 
the fact that periodic retrospective reviews have identified 
numerous critical issues in the performance of both human 
clinical trials and preclinical research. Nonetheless, numerous 
proposals based on “lessons learned” do not appear to have been 
sufficient to re-engage the field of neuroprotection in stroke; in 
fact, the increased rigor and resources now being encouraged 
to improve performance of studies and trials may actually 
dissuade increased engagement, in an era of declining resources 
in this field. Recently developed neuroprotective drugs may also 
not be viewed as being sufficiently better than those that failed 
in clinical trials, particularly when a mono-therapy approach 
continues to dominate trials. It appears the neuroprotection field 
requires a new strategy. What may be required is tackling the 
“elephant in the room” – i.e., how therapeutics are chosen at the 
preclinical level for translation. 
2. Neuroprotection in Humans
2.1 Clinical Trials
Major translational issues identified in human clinical trials 
are outside the scope of this perspective but, briefly, a common 
theme noted has been an inability to reproduce several key 
conditions employed in preclinical animal model studies (Grotta, 
2002). The therapeutic dose identified pre-clinically was rarely 
achieved clinically (if known), due to poor tolerability, safety 
issues, poor blood-brain barrier permeability or inadequate 
PK/PD knowledge (Feuerstein et al., 2007). Therapeutic 
intervention in humans was almost always substantially more 
delayed from stroke onset than tested in preclinical animal 
models (or animal models showed that these delays resulted in 
loss of neuroprotection). Patients were generally not stratified 
according to stroke severity, compared to the tightly controlled 
models of cerebral ischemia commonly used in animal models 
(George and Steinberg, 2015; Minnerup et al., 2014; Kent and 
Mandava, 2016). Consequently, strokes in some patients were 
likely more severe than in animal models: all neuroprotective 
modalities will fail in those brain regions which do not receive 
timely and adequate reperfusion. Trial durations may have been 
too short. Importantly, it is generally felt that any one of these 
deficiencies was severe enough to fully account for the failure 
of clinical trials (Jonas et al., 1999; Ginsberg, 2008; Zaleska et 
al., 2009; Jonas et al., 2001). Neuroprotection largely remains 
in the doldrums at the clinical level, with a few exceptions.
2.2 The Legacy
Due to the many issues associated with the performance of 
human clinical trials, it is difficult to draw conclusions regarding 
whether the mechanism of action of a therapy contributed to 
the failure. In principle, understanding the molecular basis for 
clinical failures can lead to corrective directions for research. 
However, there has not been much impetus to reverse-translate 
the conditions in human trials to preclinical animal models, 
so opportunities to determine individual causes for each 
failure have been missed (Moskowitz, 2010). In an exception, 
following the failure of the IMAGES stroke trial on magnesium, 
a review (Meloni et al., 2006) revealed approximately 50% of 
preclinical studies reported no neuroprotection, and predicted 
the failure of the phase III FAST-MAG trial (Meloni et al., 
2013). 
Considerable uncertainty exists about how therapeutics that 
failed clinical trials might fare with suggested improvements 
in procedural failings and advancements in generalization 
and safety of reperfusion therapy. Hence, one persistent 
recommendation is to re-investigate drugs which failed in 
human clinical trials (but were successful pre-clinically), 
given the use of tPA or increasing adoption of endovascular 
therapy, coupled with adoption of improvements in better 
trial designs (Neuhaus et al., 2017; Garber, 2007). However, 
this approach assumes that more recently developed drugs 
and therapies would represent no improvement, which seems 
unlikely. Implicit in this approach is the notion that it is not 
important (or possible) to rank drugs/therapies according to 
their neuroprotective potential. And, as discussed below in the 
preclinical section, the rigor and stringency of preclinical work 
has generally improved in past efforts.
A concern is that neuroprotection alone may be insufficient 
if the entire neurovascular unit is not preserved (Lo, 2008; 
Moskowitz et al., 2010). Neuroprotection might have been 
achieved in clinical trials (although this is unlikely), but 
this might have been masked by a failure to protect other 
components of the neurovascular unit. Hence, the neuro-centric 
view that has typically prevailed may be destined to fail in 
principle. However, given the relatively high susceptibility 
of neurons to ischemia, achievement of neuroprotection must 
be regarded as a cornerstone, whether achieved by direct or 
indirect means. 
2.3 Tackling the Legacy
The widespread abandonment of neuroprotection clinical 
trials suggests a lack of confidence in any one or more of the 
requirements to achieve success, including timely application 
directed at the appropriate target(s) and tissue at a sufficient 
dose in properly stratified patients. However, some progress 
is being made. Multimodal imaging studies continue to 
improve in delineating penumbral regions – or core regions if 
reperfusion is initiated fast enough – which may be amenable 
to neuroprotection (Zerna et al., 2016). Reduction in “door-
to-needle” times and improved functional outcomes resulting 
from intravenous thrombosis and endovascular intervention 
are being made in stroke centers (Saver et al., 2015a). In 
addition, in the FASTMAG phase 3 trial, three-quarters of 
patients received treatment within the “golden hour” (the first 
60 min from stroke onset) in a pre-hospital setting (Saver 
et al., 2015b). The ongoing FRONTIER trail evaluates if 
administration by paramedics in an out-of-hospital setting of 
NA-1, which uncouples the post-synaptic density protein PSD-
95 from excitotoxic signaling pathways (Aarts et al., 2002), 
reduces disability in stroke patients in Canada (clinicaltrials.
gov NCT02315443). The cohort of patients potentially eligible 
to receive a neuroprotective treatment is expected to increase, 
based on recent studies suggesting that transient ischemic 
attacks or minor strokes do indeed possess the capability to 
induce long-term neurodegeneration (Zamboni et al., 2017; 
Bivard et al., 2018). Moreover, very recent clinical trials 
suggest that endovascular treatment may extend the window 
of intervention (Albers et al., 2018; Nogueira et al., 2018). 
Thus, the pool of patients potentially eligible to receive 
neuroprotection may increase considerably.
2.4 Strategies in Neuroprotection – What is Missing?
Several approaches have been developed to accelerate a 
neuroprotective drug/therapy in order to circumvent certain 
kinds of limitations, including accessibility, regulatory issues, 
and mono-therapy silos. Accessing the brain by development 
of BBB-carriers or “shuttles” carrying neuroprotective cargo 
is becoming closer to reality (Webster and Stanimirovic, 2015; 
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Stanimirovic et al., 2015). Drug repurposing (or off-labelling) 
or testing of off-patent drugs has been proposed, in which 
clinically approved drugs are investigated for neuroprotective 
potential, thereby bypassing the demanding requirement 
for regulatory approval. NIH provides access to a library 
containing >1000 clinically approved drugs, some of which 
demonstrate neuroprotection (Rothstein et al., 2005; Wang et 
al., 2006a; Hill et al., 2014). Big pharma has also been granting 
access to abandoned compounds (Allison, 2012), and other 
such examples exist. Another approach is mono-therapy which 
is multi-target in nature, in which one drug exerts an effect at 
multiple targets in the neurotoxic or NVU toxicity signaling 
pathways (Lapchak, 2011; Lapchak et al., 2011; Woodruff et al., 
2011) but, as an example, albumin failed in a recent clinical trial 
(Martin et al., 2016; Ginsberg et al., 2013). Hypothermia targets 
several neurotoxic pathways, as well as the neurovascular unit, 
and preclinical evidence suggests continued pursuit of this 
strategy is warranted (van der Worp et al., 2007). 
To combat the pervasive mono-therapeutic mentality 
that has existed throughout the translational pipeline and in 
regulatory practices for neuroprotection, actual combinations 
of drugs/therapies should result in more effective targeting 
of neurotoxic pathways, potentially allowing synergistic 
neuroprotection and decreased dosing (resulting in fewer 
adverse effects). Consequently, one tactic which circumvents 
intellectual property issues and presumably costs is to evaluate 
a combination of drugs or therapies which are off-patent or not 
subject to intellectual property concerns. This concept propelled 
initiation of a small trial using magnesium, Lipitor, minocycline, 
albumin and hypothermia, in which the authors claimed, “five 
different areas where you can target the brain – if this does not 
work, then nothing would work” (Garber, 2007). A subsequent 
preclinical study examining magnesium sulphate, melatonin 
and minocycline together did not observe neuroprotection, 
even with shorter occlusion durations (and therefore smaller 
infarct volumes) (O'Collins et al., 2011). It cannot be 
emphasized enough that a risk with any of these approaches 
– re-investigation of drugs, drug repurposing, a multi-modal 
drug, or combinations directed exclusively at neurons or the 
NVU at large – is they may not represent a sufficiently targeted 
approach, due to a lack of a strong experimentally driven 
rationale, in which crucial steps in the neurotoxic (and NVU) 
pathway(s) are being targeted at an appropriate dose with 
sufficient potency in a temporally relevant manner.
3. Neuroprotection in Animal Models
3.1 Preclinical Studies
A major repercussion of the numerous issues identified in 
human clinical trials is considerable uncertainty as to the true 
neuroprotective potential of the drugs being investigated, and 
therefore whether the preclinical animal models of cerebral 
ischemia are relevant. In fact, the failures in human clinical 
trials of drugs which showed neuroprotection in animal models 
of cerebral ischemia have also led to the perception that such 
models are not predictive or translatable (“everything works in 
animals but not in humans”). Certainly, limitations and trade-
offs with animal models of cerebral ischemia are acknowledged 
(Sommer, 2017). However, as discussed above, clinical trials 
generally have not reproduced laboratory conditions, and 
therefore cannot be used as the basis for concluding that in vivo 
animal models are not predictive.
3.2 The Legacy
It may not even be true that demonstrations of neuroprotection 
in in vivo animal models are sufficiently robust. Numerous 
issues have been identified in the performance of preclinical 
studies (Perel et al., 2007; Dirnagl and Endres, 2014; Dirnagl, 
2016). The Stroke Therapy Academic Industry Roundtable 
(STAIR) has been updated several times (1999; Albers et al., 
2011), with major recommendations including defining the drug 
dose-response curve and its time window of efficacy in state-
of-the-art models of both permanent and transient occlusions; 
testing a drug in more than one species, especially non-human 
primates; integrating co-morbidity into the models (co-morbidity 
such as hypertension can reduce efficacy of neuroprotectants 
(Howells and Macleod, 2013)); more evaluation of longer-term 
functional outcomes; and further incorporation of endovascular 
treatment (Jovin et al., 2016). Animal models should be chosen 
to improve mimicry of strokes and physiological conditions in 
humans (Adkins et al., 2009).
In addition, improved rigor in the performance and reporting 
of preclinical animal model work is being increasingly 
encouraged (Dirnagl, 2006; Sena et al., 2007; Howells 
et al., 2012). As well, studies should be performed in a 
blinded, unbiased manner, adequately powered to detect a 
neuroprotective effect, combined with adoption of procedural 
refinements of in vivo experiments (Macleod et al., 2004; Sena 
et al., 2010; Percie du et al., 2017; Howells and Macleod, 
2013). Other major proposals include emulating multicenter 
stroke trials by preclinical testing of a treatment across several 
laboratories (Bath et al., 2009; Howells et al., 2012; Dirnagl 
and Fisher, 2012; Kimmelman et al., 2014; Llovera and Liesz, 
2016). A National Institute of Neurological Disorders and 
Stroke Consensus group recent meeting, resulting in proposals 
aimed at improving translational stroke research, advocates 
separation of preclinical studies into two types, with exploratory 
studies first employed to identify mechanisms of action and 
high-priority candidates, followed by confirmatory studies 
in different models and laboratories to build confidence for 
translation (Bosetti et al., 2017).
3.3 Tackling the Legacy
These calls to action are important, but widespread adoption 
and implementation may be challenging on a number of levels 
(Howells and Macleod, 2013). These refinements in preclinical 
research may be viewed as restrictive or infeasible or, even 
if implemented, insufficient to improve predictability of how 
therapeutics might fare in clinical trials. Some approaches 
require a change in mindset, by convincing laboratories 
to perform confirmatory studies, which in turn requires 
acceptance by journals, editors, academia, granting agencies 
and other parties which can affect publishing, funding and 
career progression. Moreover, a multi-laboratory preclinical 
confirmatory approach adhering to best practices (proper 
statistical analyses, adequately powered studies, double-
blinding, randomization and other bias-eliminating approaches) 
likely represents a greater commitment of resources. Thus, from 
resource and systemic standpoints, it will be very important to 
have a sound basis in choosing which neuroprotective modality 
moves from exploratory to confirmatory studies in vivo. 
Another pressure being brought to bear on stroke research 
is its cost, both in absolute and relative terms. The failure of 
all neuroprotective human clinical trials has resulted in an 
exodus of stroke research in pharma, academia and government 
laboratories. This perspective alone places further pressure on 
candidates entering human clinical trials to succeed, in order 
to generate the kind of momentum needed to re-energize the 
research community. Even when optimism was higher two 
decades ago, funding by granting agencies was far lower 
for stroke compared to cancer, based on the relative degree 
of economic impacts exerted on society by these diseases 
(Rothwell, 2001; Luengo-Fernandez et al., 2015). Of course, 
advances in neuroprotection in stroke may not derive from 
strictly targeted work, which makes general funding for 
basic research important. This too is generally in decline. 
Consequently, aside from the enormous burden stroke exacts 
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upon society (Flynn et al., 2008), from an economic standpoint 
of drug discovery, it has become even more important to 
wisely choose therapeutics at the earliest stage possible in the 
translational ladder.
3.4 Strategies in Neuroprotection – What is Missing?
Substantive neuroprotection may not be achieved even with 
adopting the numerous recommendations and approaches 
emanating from clinical human trials and preclinical animal 
studies. This may be because progress has arguably been 
insufficient in deciphering how a therapeutic might fare. 
Simply put, it does not appear that the crisis of confidence 
facing the neuroprotection field has abated with the current 
catalog of therapies, nor does it seem this is changing with 
new developments. The elephant in the room may be how 
to properly rank therapeutics which have the best chance for 
translation. 
Having Too Many Choices…
First, a major issue facing the neuroprotection field is the 
sheer number of possibilities. Indeed, it is ironic that the 
acute neuroprotection field is awash in many ostensibly very 
efficacious preclinical therapies, yet devoid of clinical approval. 
The preconditioning field (see below) faces a common challenge 
– and perhaps even more so – with myriad genomic, proteomic 
and signaling mechanisms having been identified in many 
different kinds of preconditioning stimuli. (One perplexing 
issue is that it is not at all clear how such diverse stimuli can 
result in reductions in infarct injury in vivo and neuroprotection 
in vitro (Moskowitz et al., 2010).)
….Requires Prioritization
Second, “lessons learned” have been largely focused on 
improving the process of testing/verifying a therapeutic, but 
not on how to choose a therapeutic. The challenge of how to 
prioritize a neuroprotective modality was quantitated over a 
decade ago in a landmark study by O’Collins et al. (2006), 
who reported that drugs used in human clinical trials of stroke 
performed no better than any others in animal model tests of 
cerebral ischemia. Other research groups report a similar lack 
of strong basis in preclinical studies for proceeding to clinical 
trials (van der Worp et al., 2005). Despite this recognition, 
this situation does not appear to have improved (Philip et al., 
2009). Recent entrants into clinical trials may indeed represent 
improvements based on current understanding of cerebral 
ischemia and pharmacology, but how would we know? How 
do we discern which neuroprotective strategy offers the highest 
therapeutic index, identified at the earliest stage possible, 
particularly in an era in which performance standards are 
increasing and engagement is declining? Clearly, it would be 
advantageous to have a strategy to prioritize neuroprotective 
treatments and eliminate unworthy candidates, particularly 
given the high number and variety of candidates. Pursuit of 
such a mindset may engender increased confidence and re-
engage the neuroprotection field.
As important as it is to understand how a therapy will 
succeed, it is even more important to understand – and indeed, 
actively pursue – the failure of therapeutics, as early in the 
translational pipeline as possible. This mantra of “fail early” is 
usually regarded as a fundamental tenet in the pharmaceutical 
industry, although clearly not to a great enough extent in the 
neuroprotection in stroke field. The mantra must considerably 
expand to include this field as a whole, requiring that societal 
and mechanistic-based silos be broken down.
4.The Case for In Vitro
4.1 Translation From in Vitro to in Vivo to Clinical
In vitro preparations (neuron/astrocyte cultures, brain slices) 
may be of use in understanding why many neuro-based 
treatments failed in clinical trials and, with certain modifications, 
to assist in prioritizing therapeutics for translation. In vitro 
preparations are typically restricted to screening within-family 
candidates, investigating mechanisms and demonstrating proof-
of-concept of neuroprotection, subsequently followed up by an 
in vivo model of ischemia (which generally correlates quite well 
with in vitro results). Given the demands of in vivo studies, and 
the multitude of candidates among which to choose, it would be 
quite useful if in vitro preparations could also help to prioritize 
neuroprotective drugs/therapies – as well as combinations – 
prior to translation to the in vivo animal model setting. 
Concerns about the reductionist nature of using in vitro 
preparations to model ischemia have generally precluded 
prioritization exercises, but a body of work suggests stronger 
consideration may be merited. In vitro studies can be quite 
predictive of neuroprotection in vivo and in humans. Some 
drugs which failed in clinical trials have also failed in in vitro 
studies. For instance, anti-excitotoxic-based in vitro studies have 
shown that rank order of neuroprotection in “stroke in a dish” 
models in neuron cultures varies as MK-801 > memantine > Mg 
≥ voltage-gated Ca2+ antagonists, correlating with in vivo data 
(Seif el et al., 1990; Gorgulu et al., 2000; Kimura et al., 1998; 
Koretz et al., 1994; Pringle, 2004). Magnesium represented a 
major milestone by being administered in a pre-hospital setting, 
but it nonetheless failed in the FASTMAG trial; potency is a 
major concern, since this NMDA receptor antagonist loses its 
neuroprotective properties at depolarized membrane potentials 
that occur during ischemia in vivo and in vitro. In both in vitro 
and in vivo experiments, neuroprotection by NMDA receptor 
antagonists correlates with potency, but is lost if administration 
is delayed too long after the insult (Hartley and Choi, 1989; 
Tauskela et al., 2016). In a clinical trial, administration of the 
NA-1 peptide after endovascular repair surgery resulted in a 
decrease in the number (but not volume) of ischemic infarcts 
(Hill et al., 2012), and is now in phase 3 clinical trials; this drug 
first demonstrated neuroprotection in vitro (Aarts et al., 2002), 
which translated to rodent and non-human primate models of 
cerebral ischemia (Bratane et al., 2011; Cook et al., 2012). 
4.2 Ranking Acute Neuroprotection
One method which might help identify higher priority 
candidates is to increase the harshness of an in vitro neuron 
culture (or brain slice) insult, thereby allowing rank orders 
of neuroprotection to be determined (and, in so doing, allow 
identification of the most deleterious neurotoxic pathway(s)). 
For instance, exposing neurons to an insult, such as oxygen-
glucose deprivation (OGD), lasting long enough to kill some 
neurons (lethal insult) to a longer duration capable of killing 
neurons many times over (supra-lethal insult) has led to the 
following conclusions: first, increasing the concentration of 
a drug can increase its neuroprotection, but all drugs reach a 
plateau with increasing duration of OGD, beyond which they 
fail; second, each mono-therapy fails at a different duration 
of OGD, thereby providing a rank order of neuroprotection; 
and last, combining the strongest neuroprotective agents 
(targeting different pathways) allows neurons to surpass their 
individual plateaus and to permit longer durations of OGD to 
be withstood (Bickler and Hansen, 1994; Lynch, III et al., 1995; 
Aarts et al., 2003; Bonde et al., 2005; Gwag et al., 1995; Kaku 
et al., 1993). Overall, the ability of neurons to withstand such 
extended durations of OGD in the presence of combinations 
of high concentrations of primarily anti-Ca2+ based antagonists 
reveals an extensive gap between the degree of neuroprotection 
achievable in vitro, versus what is possible in vivo (tolerability 
and accessibility issues preclude this kind of therapy). Thus, the 
field of neuroprotection may be guilty of considerably under-
estimating therapeutic armadas required for neuroprotection 
against stroke in humans, before even considering issues 
of patient stratification, re-perfusion and brain delivery. 
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Ranking neuroprotection candidates can take other forms. For 
instance, using the example supplied above of testing >1000 
clinically approved drugs for re-purposing, many candidates 
demonstrating neuroprotection during an insult failed if applied 
after the insult (Wang et al., 2006b; Beraki et al., 2013). Other 
“stroke in a dish” models might be those intended to be more 
representative of the extracellular milieu during stroke (Vornov 
and Coyle, 1991; Rytter et al., 2003; Cronberg et al., 2004).
4.3 The Future of In Vitro – Human Neurons and Cells
A concern with in vivo (and in vitro) models of ischemia is 
that the mechanism of cell death in rodent neurons or tissues 
may be different from that in humans. Recent advances in 
human iPSC-derived neuron cultures – and perhaps eventually 
3-dimensional cultures comprised of components of the NVU 
– should be able to provide considerable insight into this 
question (Antonic et al., 2012; Holloway and Gavins, 2016). 
Importantly, recent studies suggest that excitotoxic components 
of OGD are similar between in vitro rodent and human neuron 
cortical cultures (Gupta et al., 2013; Xu et al., 2016). It will be 
important to determine if supra-lethal insults result in the same 
pharmacological profile as observed in rodent neuron cultures. 
4.4 The Future of In Vitro – Multi-Electrode Arrays 
Recent advances in evaluation techniques and throughput of 
therapeutics tested in in vitro neural preparations may be of 
considerable value in prioritizing therapeutics to be translated 
for in vivo testing. The gold standard in electrophysiological 
testing is patch-clamp, but this technique requires considerable 
expertise, is a terminal experiment, and has low throughput 
(high-throughput patch-clamp has not yet been developed 
sufficiently for analysis of adherent cells such as neurons). 
Multi-electrode array (MEA) electrophysiology is making 
considerable inroads. MEAs allow long-term non-invasive 
monitoring of electrical activity (spontaneous or evoked) in 
cultured neurons. MEAs could be very useful in predicting if a 
drug is tolerable or not by determining the degree to which and 
nature of how neural electrical activity in vitro is altered. This 
would apply to therapeutics meant to be applied acutely, since 
numerous clinical trials have failed due to tolerability issues. 
Also, although preconditioning evokes an endogenous stress 
response, many agents represent potential neurotoxins. Thus, 
evaluation by MEAs may provide some valuable insight into 
the degree of tradeoff required between degrees of protection 
versus stress response required. 
Graph theoretical analyses of cultured neurons have provided 
considerable insight into network function, in a credible fashion, 
with traits such as population bursts, neuronal hubs of activity, 
and avalanches, also identified in vitro, in vivo and in humans. 
Recent advances in the number of electrodes (>4000) or use of 
48-well MEA plates will allow higher-order network analyses 
or higher throughput, respectively. MEAs are almost always 
employed in characterizing human neurons and, by measuring 
the effect of agonists/antagonists of major excitatory/inhibitory 
neurotransmitters or transporters on electrical activity, allow a 
detailed depiction of functional receptors and transporters (on 
a single electrode or neuron basis if required). Thus, MEAs 
should represent a considerable advance from imaging or 
simple live-dead analyses (Frank et al., 2018), to determine if a 
neuroprotective maneuver – either acute, conditioning or both 
combined – truly preserves neuronal function and truly retains 
central hallmarks of network function (Vincent et al., 2013; 
Tauskela et al., 2008). 
5. Conditioning
5.1 The Concept
Conditioning (pre-, per- or post-) for the purposes of 
neuroprotection against cerebral ischemia has been of academic 
interest for some time (Wang et al., 2015), and is now starting 
to enter the clinical trial arena (Keep et al., 2014). Conceptually, 
conditioning can in principle address some major mechanistic 
and procedural challenges associated with acute neuroprotective 
approaches. By definition, preconditioning is applied pre-
emptively, while acute neuroprotection implies treatment soon 
after onset of cerebral ischemia. The pre-emptive requirement 
would likely restrict widespread application, but situations can 
be envisioned in which patients at high risk for stroke within 
their immediate future may be candidates for preconditioning. 
Several features of the mechanisms underlying brain self-
protection are also observed when conditioning is applied 
following ischemia (post-conditioning), suggesting that timing 
may not be a limiting factor in implementation of stimulation 
of endogenous neuroprotection in a clinical setting. The 
endogenous nature of the response elicited by preconditioning 
suggests potentially better tolerability compared to conventional 
exogenous acute neuroprotection. Preconditioning generally 
exerts a bimodal mechanism of action: neuroprotective 
signal transduction pathways are up-regulated and neurotoxic 
pathways are down-regulated, often in a balanced approach. 
In contrast, acute neuroprotective drugs usually involve 
suppressing a specific function, risking interference with normal 
function (e.g., blocking excitotoxicity with an NMDA receptor 
antagonist also inhibits glutamatergic signaling in stroke-free 
regions (Hoyte et al., 2004)). 
Figure 1. Prioritization of neuroprotective therapeutics and 
combinations. Subjecting neuron cultures to increasingly longer 
durations of a stroke-like insult, an oxygen-glucose deprivation 
(OGD) continuum, can be used to prioritize neuroprotective 
therapeutics and identify the most efficacious combinations, in 
an experimentally driven manner. Preconditioning stimuli differ 
in the ability to protect neurons under severe conditions: strong 
preconditioners (PCstrong) protect more neurons at durations of OGD 
for which weak preconditioners (PCweak) are no longer able to protect 
neurons. At even longer durations, all preconditioning fails to protect 
neurons, correlating with an inability to suppress a neurotoxic rise 
in extracellular glutamate levels. Neurons are rescued by adding 
an NMDA receptor antagonist (labelled ACUTEweak) just prior to this 
rise (i.e., at an earlier time point for neurons subjected to PCweak 
compared to PCstrong). Extending the duration of OGD even longer 
results in loss of neuroprotection again. If, however, a cocktail of 
anti-Ca2+ agents (labelled ACUTEstrong) is applied at this juncture 
instead of a single NMDA receptor antagonist, neuroprotection can 
be restored. Thus, the severity of the insult dictates the nature of the 
treatment required.
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Preconditioning can be applied as one stimulus, but 
it has a massive polytherapy effect, activating and de-
activating numerous genomic, proteomic and signaling 
pathways. Preconditioning in some instances may be able to 
circumvent the issue of adequate brain targeting if the brain 
can be preconditioned in a paracrine manner, therefore not 
requiring direct access to the brain. For instance, ischemic 
cuff preconditioning may result in generation and transport of 
neuroprotective effectors to the brain (Moskowitz and Waeber, 
2011). Just as for re-purposing in the acute neuroprotection 
field, some drugs already in human clinical use have been 
shown to precondition against cerebral ischemia in vivo (Gidday, 
2010). As another example of potentially better accessibility, 
we discuss our experiences with nutraceutical preconditioning 
below. 
Given the backdrop of failure in human neuroprotection, 
it is appropriate to ask if preconditioning is ready for 
attempting translation from animal models to humans and, 
if not, what can be done at the preclinical level to improve 
the chances of achieving success (Mergenthaler and Dirnagl, 
2011). To do otherwise may doom conditioning, resulting in 
yet another proverbial nail in the coffin of neuroprotection. 
Conceptually, preconditioning represents a departure from acute 
neuroprotection, but there are also some important parallels, so 
some lessons learned with acute neuroprotection may be applied 
to preconditioning. 
5.2 Ranking Preconditioning
Borrowing from the acute neuroprotection literature, we have 
employed supra-lethal OGD in neuron cultures to test a panel 
of neuronal-targeted preconditioning paradigms – chosen 
based on a wide range of signaling mechanisms – leading 
to several conclusions as to how preconditioning might be 
ranked (Tauskela et al., 2016): (i) A rank order of efficacy was 
determined for this panel according to the ability of neurons to 
survive increasingly longer durations of OGD, and a chronic 
preconditioning stimulus evoking homeostatic downward 
synaptic scaling was the most neuroprotective. So, to augment 
Nietzche’s quote commonly espoused by the preconditioning 
community, “That which does not kill us makes us stronger,” 
we would add, “…but may not make us strong enough.” (ii) 
Extending the duration of OGD still further (supra-lethal insult) 
resulted in loss of neuroprotection by all preconditioners, 
correlating with an inability to no longer prevent cellular release 
of glutamate. (iii) In comparison, supra-lethal OGD did not kill 
cultures co-incubated with MK-801, suggesting superiority over 
any preconditioning stimulus. (iv) A novel combination therapy 
was developed based on the presynaptic- and postsynaptic-based 
mechanisms of preconditioning and MK-801, respectively: 
specifically, preconditioned cultures could be rescued by timely 
addition of MK-801 late in the stage of supra-lethal OGD 
(when extracellular glutamate levels were rising to neurotoxic 
levels). So, a further extension of Nietzche’s quote might be, 
“That which does not kill us, makes us stronger…but may not 
make us strong enough…so additional support is required.” As 
indicated above, an NMDA receptor antagonist will also fail if 
the duration of OGD is further extended, requiring a cocktail of 
high concentrations of antagonists to provide neuroprotection 
under these conditions (Fig. 1).
Limited in vitro and in vivo studies performed elsewhere 
agree with the concept that preconditioning delays – but 
does not prevent – damage with prolonged insults, and the 
concept of ranking. The ischemic preconditioner tested also 
reached a plateau of neuroprotection if the severity of the 
ischemic insult was increased (Liu et al., 1992; Shamloo and 
Wieloch, 1999). Nowak’s group reported that preconditioning 
merely delayed but did not prevent ischemic depolarization 
in rat (although not in gerbil), which was termed pseudo-
preconditioning, since tolerance reflected a decrease in the 
time the brain was subjected to ischemic depolarization, a 
key determinant in brain injury (Ueda and Nowak, Jr., 2005). 
Similarly, chemical preconditioning (3-nitropropionic acid) 
also delayed depolarization in hippocampal slices (Aketa et al., 
2000). Epileptiform preconditioning also failed with increasing 
severity of cerebral ischemia (Plamondon et al., 1999). Other in 
vitro (Meloni et al., 2002) and in vivo (Freiberger et al., 2006) 
studies limited in scope nonetheless are consistent with different 
preconditioners providing a relative ranking order. 
5.3 Combination Therapy – Preconditioning “Buys Time” for 
Acute Drug Intervention
A crucial advantage of preconditioning is therefore to “buy 
time” before acute pharmacology is needed during the insult, at 
least in vitro. Improvements to each of these two phases should 
be investigated. For the preconditioning phase, it is not known 
if combining preconditioners targeting different signaling 
pathways in neurons – or in astrocytes and glia present in 
neuron cultures – provides further improvement; i.e., further 
delaying the time during supra-lethal OGD before acute therapy 
is required. 
For the acute phase, it is necessary to evaluate substituting 
MK-801 with better-tolerated drugs or therapies, with one 
possibility being the anti-excitotoxic NA-1 or other peptide-
based or small molecule protein-protein inhibitors. Such an 
approach could consider post-conditioning, and a strategy is 
required to empirically determine what type of post-ischemic 
treatment provides the best therapeutic index. Combinations 
of the acute treatment may need to be considered for longer 
durations of ischemia. Interestingly, the combination of remote 
ischemic perconditioning 2 h following embolic middle cerebral 
artery occlusion in mouse and intravenous tPA at 4 h provided 
additive neuroprotection (Hoda et al., 2012). Similarly, the 
combination of pre- or post-conditioning with an acute drug 
Figure 2. The virtuous circle of pleiotropic conditioning. It will be 
necessary to develop pleiotropic conditioners possessing additional 
capabilities beyond directly conferring neuroprotection, in order 
to enhance survival of the brain after stroke. Targeting of the 
neurovascular unit (NVU) is desirable, ranging in effects from 
vasodilation of blood vessels to survival-promotion of glia, setting 
the stage for enhanced neuroplasticity. 
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provided better neuroprotection than either alone (McMurtrey 
and Zuo, 2010). There is a considerable need to build upon this 
basic neuroprotective combination framework. 
5.4 Alpha-Linolenic Acid (ALA-) Preconditioning
Due to the efficacy limitations identified in the primarily 
neuronal-targeted presynaptic-based preconditioners evaluated 
in vitro, it will be necessary to consider pleiotropic conditioners, 
which possess additional or other capabilities beyond directly 
conferring neuroprotection, such as displaying abilities to target 
the neurovascular unit. In such circumstances, these types of 
preconditioning agents may fail the supra-lethal OGD test in 
vitro but may well yield higher efficacy in in vitro and in vivo 
ischemia models adapted to allow as effective a ranking of 
agents as possible. Apart from neurons, glial or endothelial 
cells have been successfully preconditioned by many stimuli, 
so multi-model conditioners able to target the NVU in as 
comprehensive a manner as possible should be considered 
(Poinsatte et al., 2015; Stowe et al., 2011). The vasculature is 
recognized as a key target to truly protect brain (Lo, 2008). 
There is increasing evidence that preconditioning stimuli, 
in addition to improving neuronal resistance to stroke, also 
improve cerebrovascular function (Gidday, 2006) (Fig. 2).
ALA is an omega-3 fatty acid contained in plant-derived 
edible products. Our research suggests ALA is representative 
of a direction to follow in order to address several of the 
deficiencies outlined above. ALA represents a combination 
of a pleiotropic preconditioner as well as neuroprotective and 
neuro-restorative features, reviewed in Blondeau (2016). ALA 
preconditioning induces NFĸB, HSP70, BDNF, SNAREs and 
V-GLUTs, inducing tolerance against two models of neuronal 
death by excitotoxicity induced by kainic acid injection and 
global ischemia. ALA preconditioning promotes robust basilar 
artery dilation, and therefore increases residual cerebral blood 
flow circulation during ischemia. Intravenous injections of ALA 
were neuroprotective in animal models ranging from spinal cord 
injury (Lang-Lazdunski et al., 2003; King et al., 2006; Michael-
Titus, 2007) to brain ischemia (Lauritzen et al., 2000; Blondeau 
et al., 2001; Lang-Lazdunski et al., 2003; Heurteaux et al., 
2004; Heurteaux et al., 2006; Blondeau et al., 2002; Blondeau 
et al., 2007). Moreover, sequential injections of ALA given in 
the days following ischemia – a protocol could be assimilated to 
post-treatment as well as post-conditioning – promote long-term 
survival. Finally, a key component of this form of conditioning 
is how it is administered: the benefit of preconditioning 
could be achieved through dietary supplementation, since 
oral supplementation with ALA reproduced the benefit of 
ALA preconditioning achieved by injection by also reducing 
mortality rate and ischemic lesion size (Nguemeni et al., 2010), 
as well as improving motor and cognitive recovery after 30 min 
of temporary focal cerebral ischemia (Bourourou et al., 2016). 
Put in perspective with epidemiological results demonstrating 
that ALA intake is associated with a lower risk of stroke, the 
selection of such a natural substance that can neuroprotect the 
brain in a preconditioning and acute manner suggests that a 
nutraceutical-based approach represents a paradigm shift in the 
management of ischemic stroke to circumvent administration 
and timing issues of traditional drug approaches. 
6. Conclusions
The field of neuroprotection in stroke is at a crossroads. The 
legacy of failure in human clinical trials has resulted in a 
seemingly unassailable challenge permeating to preclinical 
levels of investigation. A number of practical criteria are 
converging to a point which now requires tackling how a 
therapeutic is prioritized within the translational pipeline. 
Solutions have been offered to improve the rigor of preclinical 
animal model work but, in an era of ever-shrinking resources, 
this makes the choice of a therapeutic to be tested in preclinical 
animal models more important than ever. A myriad of 
treatment possibilities exists among conditioning and acute 
neuroprotection, many targeting a seemingly endless array of 
neurotoxic mechanisms. A framework of experimentally driven 
prioritization is required at the earliest stage of investigation 
possible, prior to entry into in vivo animal model work. In 
essence, success can be achieved by actively pursuing failure. 
In an already extremely difficult field, pursuing this path can be 
fraught with challenges, both within and outside the laboratory: 
it requires overcoming a silo mentality which is mechanistic 
in nature (since combination therapy will probably represent 
the best chance of achieving substantive neuroprotection), and 
requires cross-pollination among the many different kinds of 
societal-based contributors to the neuroprotection field. No 
longer should investigators be restricted to their particular 
sub-field or vantage point. We have suggested that proof-in-
principle of the kind of prioritization required can be first 
gained by adjusting in vitro models to fail most approaches. 
We encourage the neuroprotection field to adopt a mindset of 
seeking prioritization to increase predictive value in translation. 
This approach of focusing on neuroprotection first at the in 
vitro level is not to exclude therapies adept in targeting the 
neurovascular unit in vivo. This can be a parallel process, and 
we have highlighted preconditioning, particularly by ALA, 
since this moiety also possesses acute effects on the NVU.
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